Cerebrolysin treatment

PreclinicalSmall molecule

UUniversity Medical Centre Ljubljana

Cerebrolysin treatment is one of 31 small molecule programs targeting Stroke. It is currently in Preclinical.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

StrokeActive, not recruiting

StrokePreclinical

Active, not recruiting

Competition

Competitive Landscape

461 competitors in Stroke

#DrugCompanyPhaseTrials

Activase

Roche

Preclinical

19 2

Zometa

Pfizer

Preclinical

1 3

Folvite

Eli Lilly

Preclinical

1 4

Proamatine

Takeda

Preclinical

—5

Botox

RRevance Therapeutics, Inc.

Preclinical

2 6

Alka-Seltzer

AAbbott

Preclinical

1 7

Direct Anticoagulant

Bayer

Preclinical

3 8

Inderal

Mylan Pharmaceuticals Inc

Botulinum Toxin a

1 10

Anticoagulants

Sanofi

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Stroke

NCT07043686

Clinical

Trials by Indication[1]

Stroke1 trial

Cerebrolysin in Early Stroke Rehabilitation - Tertiary Study

Recruiting·UUniversity Medical Centre Ljubljana·N/A·NCT07043686·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Cerebrolysin treatment. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Cerebrolysin treatment compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Cerebrolysin treatment. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University Medical Centre Ljubljana company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Preclinical[1]
Company: UUniversity Medical Centre Ljubljana

Cerebrolysin treatment

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Trials by Indication[1]

Stroke1 trial

References

Drug Info

Quick Facts

Related News